Can Magnetic Brain Stimulation Help Prevent Relapse in Depression?

Sponsor
University of Manitoba (Other)
Overall Status
Terminated
CT.gov ID
NCT02029963
Collaborator
Manitoba Medical Service Foundation (Other)
21
1
3
93.3
0.2

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the use of repetitive transcranial magnetic stimulation (rTMS) in helping to prevent relapse in major depressive disorder. rTMS is known to be an effective treatment for major depressive disorder, but there is also evidence that it may be effective in the maintenance of remission following treatment. However, it is not yet clear what maintenance strategy will yield the best outcome in preventing relapse.

In this study, eligible patients who have finished one full course of rTMS for treatment of major depression will be randomized into three groups: (i) cluster rTMS, (ii) taper rTMS, and (iii) treatment as usual. The 'cluster rTMS' group will receive two weeks to daily rTMS six months after the completion of their regular rTMS treatment, the 'taper rTMS' group will receive three sessions a week for two weeks followed by two sessions a week for two weeks immediately following their regular rTMS treatment, while the 'treatment as usual' group will receive standard follow-up care from their own psychiatrist and/or primary care doctor.

The investigators hypothesize that the group with cluster treatment will show significantly lower relapse rates in depressive symptoms as compared to the other groups.

Condition or Disease Intervention/Treatment Phase
  • Device: Transcranial Magnetic Stimulation (rTMS)
  • Behavioral: Treatment as Usual
N/A

Detailed Description

The purpose of this study is to investigate the efficacy of rTMS to the dorsolateral prefrontal cortex (dlPFC) as a maintenance therapy following standard rTMS treatment in major depressive disorder.

A total of 45 patients will be recruited for this study. Patients who have completed a standard six-week rTMS treatment for major depressive disorder will be randomly assigned to one of the three groups: cluster rTMS, taper rTMS, and treatment as usual. Patients in the 'cluster' group will receive two weeks of daily rTMS (10 rTMS sessions) six months after completing their rTMS treatment. Patients in the 'taper' group will receive rTMS immediately after completing rTMS treatment and the frequency of the sessions will be tapered as follows: three sessions a week for two weeks, and then two sessions a week for two weeks. The maintenance plan for patients in 'treatment as usual' group will be decided individually and may include any or all of the following: continue or start on medication, start psychotherapy and/or follow-up visits with psychiatrist or primary care provider.

Each session of rTMS will be identical: lasting about one hour and consisting of 3000 high frequency (10 Hz) pulses. After finishing their last session of rTMS treatment, all patients will be seen by the rTMS psychiatrists bi-monthly for one year. Each visit will last approximately half an hour during which time the Hamilton Depression (Ham-D) Scale will be administered.

Given the high relapse rates following rTMS treatment for depression, the investigators hope that results from this study will be very helpful to patients suffering from major depressive disorder in improving their quality of life by reducing their rate of relapse.

Study Design

Study Type:
Interventional
Actual Enrollment :
21 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Efficacy of Repetitive Transcranial Magnetic Stimulation in Relapse Prevention of Major Depressive Disorder
Study Start Date :
Feb 1, 2014
Actual Primary Completion Date :
Dec 1, 2017
Actual Study Completion Date :
Nov 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cluster rTMS

Two weeks of daily repetitive Transcranial Magnetic Stimulation (total of 10 rTMS sessions), six months following completion of regular six-week rTMS treatment.

Device: Transcranial Magnetic Stimulation (rTMS)
A non-invasive method for brain stimulation

Experimental: Taper rTMS

Immediately following completion of regular six-week repetitive Transcranial Magnetic Stimulation treatment, patients in this group will receive three sessions of rTMS a week for two weeks followed by two sessions of rTMS a week for two weeks (total of 10 rTMS sessions tapered in 4 weeks)

Device: Transcranial Magnetic Stimulation (rTMS)
A non-invasive method for brain stimulation

Experimental: Treatment as Usual

Following their last session of regular six-week rTMS treatment, patients in this group will follow an individually-tailored maintenance plan as determined by their own psychiatrist or primary care provider

Behavioral: Treatment as Usual
An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider

Outcome Measures

Primary Outcome Measures

  1. Change in depressive symptom severity [One year with bi-monthly measurements]

    Changes in depressive symptoms will be measured through administration of the Hamilton Depression (Ham-D) Scale.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with Major Depressive Disorder

  • Patients who are not actively receiving any psychotherapy

  • Patients who are on no or only one antidepressant

Exclusion Criteria:
  • History of a psychotic episode

  • History of neurological illness

  • Previous head injury

  • Active alcohol or substance abuse

  • History of seizure disorders

  • Currently pregnant

Contacts and Locations

Locations

Site City State Country Postal Code
1 St. Boniface Hospital Winnipeg Manitoba Canada R3P2B4

Sponsors and Collaborators

  • University of Manitoba
  • Manitoba Medical Service Foundation

Investigators

  • Principal Investigator: Mandana Modirrousta, MD PhD, Saint Boniface General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Manitoba
ClinicalTrials.gov Identifier:
NCT02029963
Other Study ID Numbers:
  • B2013:178
First Posted:
Jan 8, 2014
Last Update Posted:
Nov 15, 2021
Last Verified:
Sep 1, 2021

Study Results

No Results Posted as of Nov 15, 2021